Adenoviral Vectors for Hemophilia Gene Therapy.

N Brunetti-Pierri, Philip Ng

Open access · greenAbstract read

In one paragraph

Article in Journal of genetic syndromes & gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.7field-weighted citation impact, top 24% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

Adenovirus vectors in hematopoietic stem cell genome editing.FEBS letters · 2019
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

N Brunetti-PierriTelethon Institute of Genetics and Medicine, Naples, Italy ; Department of Translational Medicine, Federico II University of Naples, Italy.

Philip NgDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

Telethon Institute Of Genetics And Medicine · IT

Funding

Improving Safety and Efficacy of Gene Therapy with HDAdR01DK067324 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI NG, PHILIP · 2005 to 2013

$3.5M

Protection of Steatotic Livers From Primary NonfunctionR01DK069369 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHAVIN, KENNETH D · 2006 to 2010

$1.4M

NIDDK NIH HHS R01 DK067324NIDDK NIH HHS R01 DK069369

6 · The paper itself

Abstract

Hemophilia is an inherited blood clotting disorder resulting from deficiency of blood coagulation factors. Current standard of care for hemophilia patients is frequent intravenous infusions of the missing coagulation factor. Gene therapy for hemophilia involves the introduction of a normal copy of the deficient coagulation factor gene thereby potentially offering a definitive cure for the bleeding disorder. A variety of approaches have been pursued for hemophilia gene therapy and this review article focuses on those that use adenoviral vectors.

Indexed as

AdenovirusFactor IXFactor VIIIGene therapyHelper-dependent adenoviral vectorsHemophilia AHemophilia BViral vectors

Identifiers

PMID24883229

PMCPMC4039643

OpenAlexW2145427420

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.